Clinical Trials Logo

Anaplastic Thyroid Cancer clinical trials

View clinical trials related to Anaplastic Thyroid Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00603941 Terminated - Clinical trials for Anaplastic Thyroid Cancer

A Phase 1/2 Study of CS7017, an Oral PPARĪ³ Agonist, in Combination With Paclitaxel

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The Phase I/II study will be conducted as an open label, multiple center study of CS-7017, an experimental drug and paclitaxel chemotherapy in subjects with advanced anaplastic thyroid cancer. Biopsies will be obtained from patients with accessible tumor at baseline, two-weeks after the first CS-7017 dosage (prior to the start of combination therapy) and at the end of the first study cycle (week 3 of combination therapy), in order to evaluate the effects of the study drug alone and in combination with the chemotherapy agent on the tumor. Treatment will continue until disease progression or the development of intolerable toxicities.

NCT ID: NCT00507429 Terminated - Clinical trials for Anaplastic Thyroid Cancer

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

FACT
Start date: August 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).

NCT ID: NCT00126568 Terminated - Clinical trials for Anaplastic Thyroid Cancer

Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with advanced anaplastic thyroid cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00095693 Terminated - Clinical trials for Anaplastic Thyroid Cancer

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.